HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Update on Psoriatic Arthritis: 3 New Things

What's new: reliable outcome measures, overlap in treatment targets, and immune checkpoint inhibitors.

1. Holland R, Tillett W, Korendowych E, et al. Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis. 2018;77:343-347. doi: 10.1136/annrheumdis-2017-2119962. Van Mens LJJ, van de Sande MGH, van Kuijk AWR, et al. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis. 2018;77. doi.org/10.1136/annrheumdis-2017-2119983. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77:393-398. doi: 10.1136/annrheumdis-2017-212257.